News Despite US turmoil, Hinge Health pushes ahead with IPO Digital health firm Hinge has published a new prospectus for its IPO, shrugging off the weakness in US stock markets caused by Trump's tariffs.
News Share in cystic fibrosis firm Sionna rise sharply after IPO Sionna has closed its IPO, raising $191m for cystic fibrosis candidates that it thinks could be more effective than rivals from Vertex.
News Two more biotechs, Metsera and Maze, cross IPO finish line Metsera and Maze Therapeutics have become the second and third biotechs to complete an IPO on the Nasdaq this year.
News Ascentage raises $126m in first biotech IPO of 2025 China's Ascentage completes the first US biotech IPO of 2025, raising $126m for its pipeline of small-molecule cancer drugs.
News AMR biotech BioVersys plans to float on Swiss stock exchange BioVersys has filed to list on the Swiss Stock Exchange, hoping to raise CHF80m for its novel antibacterial candidates.
News Two more biotechs join IPO waiting list Odyssey and Sionna have filed to carry out IPOs on the Nasdaq, following after Metsera and Maze which filed earlier in January.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.